These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

954 related articles for article (PubMed ID: 15486896)

  • 1. Role of urokinase plasminogen activator and its receptor in metastasis and invasion of neuroblastoma.
    Li P; Gao Y; Ji Z; Zhang X; Xu Q; Li G; Guo Z; Zheng B; Guo X
    J Pediatr Surg; 2004 Oct; 39(10):1512-9. PubMed ID: 15486896
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Invasion and metastasis of hepatocellular carcinoma in relation to urokinase-type plasminogen activator, its receptor and inhibitor.
    Zheng Q; Tang ZY; Xue Q; Shi DR; Song HY; Tang HB
    J Cancer Res Clin Oncol; 2000 Nov; 126(11):641-6. PubMed ID: 11079728
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhanced expression of urokinase plasminogen activator and its receptor in pancreatic carcinoma.
    Cantero D; Friess H; Deflorin J; Zimmermann A; Bründler MA; Riesle E; Korc M; Büchler MW
    Br J Cancer; 1997; 75(3):388-95. PubMed ID: 9020484
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of urokinase-type plasminogen activator/urokinase-type plasminogen activator receptor and maspin in oral squamous cell carcinoma: Association with mode of invasion and clinicopathological factors.
    Yoshizawa K; Nozaki S; Kitahara H; Kato K; Noguchi N; Kawashiri S; Yamamoto E
    Oncol Rep; 2011 Dec; 26(6):1555-60. PubMed ID: 21833477
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Urokinase-type plasminogen activator and its receptor in colorectal cancer: independent prognostic factors of metastasis and cancer-specific survival and potential therapeutic targets.
    Yang JL; Seetoo Dq; Wang Y; Ranson M; Berney CR; Ham JM; Russell PJ; Crowe PJ
    Int J Cancer; 2000 Sep; 89(5):431-9. PubMed ID: 11008205
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Expression and clinical significance of coagulate and fibrolysis factors in tissue and plasma from hepatocellular carcinoma patients].
    Zhou Q; Liang LJ; Peng BG; Zhen YY
    Ai Zheng; 2006 Nov; 25(11):1433-8. PubMed ID: 17094916
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunohistochemical localization of a urokinase-type plasminogen activator system in squamous cell carcinoma of the oral cavity: association with mode of invasion and lymph node metastasis.
    Nozaki S; Endo Y; Kawashiri S; Nakagawa K; Yamamoto E; Yonemura Y; Sasaki T
    Oral Oncol; 1998 Jan; 34(1):58-62. PubMed ID: 9659521
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Larger and more invasive colorectal carcinoma contains larger amounts of plasminogen activator inhibitor type 1 and its relative ratio over urokinase receptor correlates well with tumor size.
    Abe J; Urano T; Konno H; Erhan Y; Tanaka T; Nishino N; Takada A; Nakamura S
    Cancer; 1999 Dec; 86(12):2602-11. PubMed ID: 10594855
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients.
    Foekens JA; Peters HA; Look MP; Portengen H; Schmitt M; Kramer MD; Brünner N; Jänicke F; Meijer-van Gelder ME; Henzen-Logmans SC; van Putten WL; Klijn JG
    Cancer Res; 2000 Feb; 60(3):636-43. PubMed ID: 10676647
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Correlative studies on uPA mRNA and uPAR mRNA expression with vascular endothelial growth factor, microvessel density, progression and survival time of patients with gastric cancer.
    Zhang L; Zhao ZS; Ru GQ; Ma J
    World J Gastroenterol; 2006 Jul; 12(25):3970-6. PubMed ID: 16810742
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic implications of the co-detection of the urokinase plasminogen activator system and osteopontin in patients with non-small-cell lung cancer undergoing radiotherapy and correlation with gross tumor volume.
    Ostheimer C; Evers C; Bache M; Reese T; Vordermark D
    Strahlenther Onkol; 2018 Jun; 194(6):539-551. PubMed ID: 29340706
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Influence of overexpressed coagulant and fibrolytic components in tumor tissues on the prognosis of non-small cell lung cancer].
    Chen WH; Wang C; Zhang YH; Yang YH; Zhan HY; Zhang LM
    Zhonghua Yi Xue Za Zhi; 2007 Dec; 87(45):3228-32. PubMed ID: 18399120
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High expression of the urokinase plasminogen activator and its cognate receptor associates with advanced stages and reduced disease-free interval in papillary thyroid carcinoma.
    Ulisse S; Baldini E; Sorrenti S; Barollo S; Gnessi L; Catania A; Pellizzo MR; Nardi F; Mian C; De Antoni E; D'Armiento M; Frati L
    J Clin Endocrinol Metab; 2011 Feb; 96(2):504-8. PubMed ID: 21106716
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High level of urokinase plasminogen activator contributes to cholangiocarcinoma invasion and metastasis.
    Thummarati P; Wijitburaphat S; Prasopthum A; Menakongka A; Sripa B; Tohtong R; Suthiphongchai T
    World J Gastroenterol; 2012 Jan; 18(3):244-50. PubMed ID: 22294827
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serine proteinase activation in esophageal cancer.
    Tang WH; Friess H; Kekis PB; Martignoni ME; Fukuda A; Roggo A; Zimmerman A; Büchler MW
    Anticancer Res; 2001; 21(4A):2249-58. PubMed ID: 11724279
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumor-associated proteolysis and prognosis: new functional risk factors in gastric cancer defined by the urokinase-type plasminogen activator system.
    Heiss MM; Babic R; Allgayer H; Gruetzner KU; Jauch KW; Loehrs U; Schildberg FW
    J Clin Oncol; 1995 Aug; 13(8):2084-93. PubMed ID: 7636552
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of urokinase-type plasminogen activator, urokinase-type plasminogen activator receptor and plasminogen activator inhibitors in patients with renal cell carcinoma: correlation with tumor associated macrophage and prognosis.
    Ohba K; Miyata Y; Kanda S; Koga S; Hayashi T; Kanetake H
    J Urol; 2005 Aug; 174(2):461-5. PubMed ID: 16006865
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor stroma is the predominant uPA-, uPAR-, PAI-1-expressing tissue in human breast cancer: prognostic impact.
    Hildenbrand R; Schaaf A; Dorn-Beineke A; Allgayer H; Sütterlin M; Marx A; Stroebel P
    Histol Histopathol; 2009 Jul; 24(7):869-77. PubMed ID: 19475533
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Urokinase-type plasminogen activator, its inhibitor, and its receptor in patients with upper urinary tract carcinoma.
    Nakanishi K; Kawai T; Torikata C; Aurues T; Ikeda T
    Cancer; 1998 Feb; 82(4):724-32. PubMed ID: 9477106
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relationship between urokinase-type plasminogen receptor, interleukin-8 gene expression and clinicopathological features in gastric cancer.
    Lee KH; Bae SH; Lee JL; Hyun MS; Kim SH; Song SK; Kim HS
    Oncology; 2004; 66(3):210-7. PubMed ID: 15218312
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 48.